Journal of Clinical Oncology

Vol. 44, Issue 16_suppl Issue 16_suppl 2026
7213
Articles

Articles in this Issue

Social risk factors and treatment preferences for patients with breast cancer.

Austin Wesevich, Liam J. Schmitt, Helena Margaret Earl et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e23139

e23139 Background: Physicians often overestimate their understanding of patient preferences. While patient preferences are...

Systematic review of non-oncologic interventions for neoplastic fever.

Sarah McKenna, Hannah Segal, Clara Becker et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e24060

e24060 Background: Neoplastic fever (or “tumor fever”, TF), is a rare and challenging condition, notable for debilitating...

Real-world evidence on definitive chemoradiotherapy following neoadjuvant chemoimmunotherapy in locally advanced head and neck squamous cell carcinoma.

Ya-Ni Zhang, Zheng Wu, Wenmin Liao et al. Jun 01, 2026 pp. 6094-6094 10.1200/jco.2026.44.16_suppl.6094

6094 Background: Real-world evidence regarding the efficacy and safety of neoadjuvant chemoimmunotherapy (NACI) in the tre...

Sedative-hypnotic use peri-chemotherapy and short-term fall and fracture risk in older adults with cancer.

Maksim Isachanka, Okan Cetin, Yenong Cao Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e13765

e13765 Background: Falls and fractures are high-impact geriatric adverse events during chemotherapy. Sedative-hypnotics ar...

Long-term associations between ambient PM₂.₅ and PM₁₀ and lung cancer hospital admissions.

Sharareh Seifi, Masoumeh Nomani, Maryam Mabani et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e20092

e20092 Background: Air pollution is a significant environmental health threat worldwide and an important modifiable risk f...

Rethinking the role of tumor size in bladder preservation: Comparing survival outcomes of radical cystectomy (RC) and tri-modality therapy (TMT).

Dawood Hasan Syed, Haritha Gandicheruvu, Jennifer Kate Beckerman et al. Jun 01, 2026 pp. 4621-4621 10.1200/jco.2026.44.16_suppl.4621

4621 Background: TMT (maximal TURBT followed by chemoradiation) is typically reserved for bladder cancer (BC) patients wit...

Cell-free DNA (cfDNA) methylation-based multi-cancer early detection (MCED) assay to enable subtyping of lung cancer, breast cancer, and non-Hodgkin lymphoma (NHL).

Kezhong Chen, Jian Huang, Xiang-Yu Zhao et al. Jun 01, 2026 pp. 3047-3047 10.1200/jco.2026.44.16_suppl.3047

3047 Background: Given that distinct pathological and molecular subtypes of most cancers correspond to different treatment...

Ultrasensitive circulating tumor DNA detection and molecular clearance as a prognostic and predictive marker in advanced renal cell carcinoma.

Juan Ruiz Bañobre, Helena Lombardia-Rodriguez, Bailiang Li et al. Jun 01, 2026 pp. 4551-4551 10.1200/jco.2026.44.16_suppl.4551

4551 Background: Renal cell carcinoma (RCC) is characterized by exceptionally low levels of circulating tumor DNA (ctDNA),...

Fraction genome altered to predict survival in early-stage non–small cell lung cancer.

Mobina Shrestha, Salina Dahal, Vishal Mandal Jun 01, 2026 pp. 8042-8042 10.1200/jco.2026.44.16_suppl.8042

8042 Background: Patients with stage I-III non-small cell lung cancer (NSCLC) often have very different outcomes, even whe...

Diabetic ketoacidosis and hyperosmolar hyperglycemic state as high-acuity phenotypes in U.S. cancer hospitalizations: National Inpatient Sample, 2018–2022.

Jacob Everett, Priam Chaganlal, Daniel Thomas Jones et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e23197

e23197 Background: Diabetic ketoacidosis (DKA) and hyperosmolar hyperglycemic state (HHS) are uncommon but high-acuity eve...

CLDN18.2–targeting antibody-drug conjugate BA1301 in advanced solid tumors: Results from a phase I clinical trial.

Dan Su, Xin Wang, Yongchang Zhang et al. Jun 01, 2026 pp. 4031-4031 10.1200/jco.2026.44.16_suppl.4031

4031 Background: Aberrant expression of claudin18.2 (CLDN18.2) has frequently been observed in various solid tumors, makin...

Do mental health disorders modify cytokine release syndrome risk in immune effector cell therapy? Full-cohort analysis with tarlatamab validation.

Chad Markey, William Patterson, Kelsey Kuwahara et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e19002

e19002 Background: Cytokine release syndrome (CRS) is a common immune effector cell (IEC) therapy toxicity. Host psychiatr...

Survival and treatment patterns of patients with metastatic urothelial cancer in France: Results of a cohort study using the French National Healthcare database (SNDS).

Philippe Barthélémy, Mairead Kearney, Laura Luciani et al. Jun 01, 2026 pp. 4610-4610 10.1200/jco.2026.44.16_suppl.4610

4610 Background: Despite the increasing number of available treatment options, metastatic urothelial cancer (mUC) remains...

Phase I trial of trastuzumab deruxtecan in combination with stereotactic radiosurgery for brain metastases from HER2-positive breast cancer.

Zouina Sarfraz, Rupesh Kotecha, Bekka E. Hooks et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.tps2093

TPS2093 Background: Brain metastases (BM) develop in nearly 40-50% of patients with HER2-positive breast cancer. Stereotac...

Association of facility type with overall survival in older adults with angioimmunoblastic T-cell lymphoma: A National Cancer Database analysis.

Laura Reyes-Uribe, Henry Idrobo, Carlos Chiattone et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e19074

e19074 Background: Angioimmunoblastic T cell lymphoma (AITL) is a distinct and aggressive subtype of peripheral T cell lym...

Rituximab pre-conditioning in a phase I study of CARv3-TEAM-E for recurrent glioblastoma (GBM): The INCIPIENT trial.

Bryan D. Choi, Elizabeth R. Gerstner, William T. Curry et al. Jun 01, 2026 pp. 2059-2059 10.1200/jco.2026.44.16_suppl.2059

2059 Background: Chimeric Antigen Receptor (CAR) T cells for glioblastoma (GBM) have been limited by the challenge of targ...

RAD-SG: Adaptive radiation therapy with concurrent sacituzumab govitecan for bladder preservation in patients (pts) with muscle invasive bladder cancer (MIBC).

Shilpa Gupta, Shalini Moningi, Nima Almassi et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e16614

e16614 Background: Concurrent chemoradiotherapy (CRT) is a bladder-preserving option for patients (pts) with MIBC but is l...

Phase II trial of asciminib for newly diagnosed chronic myeloid leukemia.

Maria Hachem, Fadi Haddad, Elias Jabbour et al. Jun 01, 2026 pp. 6589-6589 10.1200/jco.2026.44.16_suppl.6589

6589 Background: Asciminib is safe and effective across all lines of therapy of chronic myeloid leukemia (CML). Here, we r...

Tisagenlecleucel (tisa-cel) in pediatric and young adult patients with high-risk (HR) B-cell acute lymphoblastic leukemia (B-ALL) and minimal residual disease (MRD) at the end of frontline consolidation (EOC).

Shannon L. Maude, Susana Rives, Joerg Krueger et al. Jun 01, 2026 pp. 10000-10000 10.1200/jco.2026.44.16_suppl.10000

10000 Background: Persistent MRD portends a high risk of relapse in B-ALL. In the Children’s Oncology Group (COG)...

TIGOS-LS, an open-label, randomized study of BMS-986489 (atigotatug + nivolumab fixed-dose combination) vs durvalumab as consolidation therapy following chemoradiotherapy in limited-stage small-cell lung cancer.

Melissa Lynne Johnson, Jerome H. Goldschmidt, Ticiana Leal et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.tps8134

TPS8134 Background: Durvalumab consolidation was added to concurrent chemoradiotherapy for standard-of-care treatment of l...

Racial demographic reporting in clinical trials supporting NCCN NSCLC guidelines.

Soumith Sanka, Sai Sushrutha Mudupula Vemula, Niket Shah et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e13739

e13739 Background: Non-Small Cell Lung cancer (NSCLC) demonstrates marked global racial and ethnic disparities in incidenc...

Mortality trends among U.S. adults with breast cancer and hypertensive diseases: A nationwide CDC WONDER analysis from 1999 to 2023.

Hassan E. Muhammad, Mifrah Rahat Khan Sherwani, Hasan Alajmi et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e12716

e12716 Background: Hypertension is a well-established risk factor for cardiovascular mortality among cancer patients and m...

Stereotactic radiosurgery (SRS) alone vs SRS + whole-brain radiotherapy (WBRT) for 1–4 brain metastases: Meta-analysis of randomized controlled trials.

Shradha P. Kakde, Niraj Arora, Meghnath P. Kakde et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e14008

e14008 Background: Whether adding WBRT to SRS improves survival for patients with limited brain metastases remains controv...

Efficacy and safety of cadonilimab plus chemotherapy and bevacizumab as second-line treatment in patients with <i>RAS</i> -mutant metastatic colorectal cancer: Preliminary findings of a multi-center, single-arm study.

Ying Yuan, Yi Lu, Jianfei Fu et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e15602

e15602 Background: To date, immune-checkpoint inhibitors remain ineffective for patients with proficient mismatch repair/m...

Acupuncture for psychoneurological symptoms in breast cancer: Symptom-specific response and sustainability.

Hannah Choi, Judith Schlaeger, Chang Park et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e24067

e24067 Background: Breast cancer survivors receiving adjuvant endocrine therapy often endure persistent psychoneurological...

All Issues

Journal Info

Publisher Lippincott Williams & Wilkins
ISSN 0732-183X
E-ISSN 1527-7755
Subject Health Sciences
Language English
View Full Journal Page